OGN Stock Surges 20% Pre-Market, On Track To Break 200-DMA – Why This Buyout Report Has Caught Investor Attention

• Sun Pharma reportedly faces competition from two global conglomerates for Organon.
• The Indian firm reportedly made a non-binding offer for Organon in January.
• Organon reported a debt of $8.64 billion as of Dec. 31, 2025, and is reportedly working with Morgan Stanley to find buyers for part of its business or the entire operation.

Shares of Organon & Co. (OGN) jumped more than 20% in pre-market trading on Friday, and are on track to breach the 200-day moving average for the first time since Jan. 28, 2026, after a report stated that India’s Sun Pharmaceutical is set to proceed with a $12 billion offer to buy out the debt-laden company.

Source: TradingView

Sun Pharma Faces Competition

According to a report by The Economic Times, Sun Pharma faces competition from two other global conglomerates – one led by a buyout fund and another backed by a strategic investor alongside a European buyout firm.

The Mumbai-based firm has completed over three months of due diligence and is now finalizing financing before submitting a binding offer in the coming weeks, the report stated. Sun Pharma had made a non-binding offer for Organon in January.

Organon, which reported a debt of $8.64 billion as of Dec. 31, 2025, is reportedly working with Morgan Stanley to find buyers for part of its business or the entire operation. The company’s cash and cash equivalents were $574 million at the end of December.

The company, which makes products for contraception, fertility, and maternal health, spun off from Merck & Co (MRK) in June 2021.

How Did Retail Traders React?

Retail sentiment on Stocktwits turned ‘extremely bullish’ from ‘neutral’ a day earlier, amid ‘extremely high’ message volumes.

One user expects the stock to climb to $10.5 in response to the buyout report.

However, another user believes the deal “isn’t great,” highlighting Organon’s liabilities.

Year-to-date, the stock has dropped nearly 4%.

Read also: Travere Therapeutics, Ligand In Focus As FDA Set To Rule On Filspari Next Week – First FSGS Drug At Stake

For updates and corrections, email newsroom[at]stocktwits[dot]com.